Skip to content
Endologix is now Rhevera Medical. Learn more about our evolution.
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Search
Back to News
April 28, 2016
Positive Nellix Clinical Data from the ASCEND Study for the Treatment of Juxta and Pararenal AAA Presented at the 38th Annual Charing Cross Symposium
Prev
Previous
Positive Nellix Clinical Data from the Global Registry and Treatment of Iliac Aneurysm Studies Presented at the 38th Annual Charing Cross Symposium
Next
Endologix Completes Patient Enrollment in the Ovation® LIFE (Least Invasive Fast-Track EVAR) Study
Next
